Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on INT 1. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN105753844A reveals convergent synthesis for Daclatasvir intermediates improving yield and atom economy. Discover supply chain advantages and cost reduction strategies.
Patent CN106928136B details graphene palladium cobalt catalysis for montelukast intermediate. Offers high yield and chiral selectivity for reliable pharmaceutical intermediate supply chains.
Patent CN112876524A reveals a scalable, high-yield route for Remdesivir intermediates, offering cost reduction and supply chain reliability for global pharmaceutical manufacturers.
Patent CN108658831A reveals high-yield Pd-catalyzed route for Brivaracetam intermediates. Enables cost reduction in API manufacturing and reliable pharmaceutical intermediates supply.
Patent CN111116419A details a novel Weinreb amide route for Treprostinil intermediates, offering significant cost reduction and improved supply chain reliability for pharmaceutical manufacturers.
Novel chiral squaramide catalyzed route for Ruxolitinib intermediate. High yield, >98% ee. Cost-effective scale-up for pharma supply chains.
Patent CN103435523B reveals a cost-effective route for Sitafloxacin intermediates ensuring supply chain stability and high purity for global pharmaceutical manufacturing partners.
Patent CN111233870A details a column-free synthesis for Remdesivir intermediates, offering significant cost reduction and scalable manufacturing for global supply chains.
Patent CN109705022A reveals cost-effective copper-catalyzed route. High purity, scalable production for pharmaceutical supply chains.
Patent CN109553649A reveals a safer low-temperature synthesis route for Canagliflozin intermediates, offering significant cost reduction and supply chain reliability for pharmaceutical manufacturers.
Novel asymmetric substitution route for Dapoxetine intermediate. High yield, scalable process for reliable pharmaceutical intermediate supply chain.
Novel patent CN105906576A offers toxic-free lesinurad intermediate synthesis. High yield 96.30% step ensures cost reduction and supply reliability for pharmaceutical manufacturing.
Patent CN106279048B reveals a novel rearrangement route for Clozapine intermediates. Achieve higher purity and reduced operational costs with scalable manufacturing.
Novel photochemical route for linagliptin intermediate avoids nitrites. High yield, mild conditions, suitable for industrial scale-up and cost reduction.
Advanced convergent synthesis of Wipatasvir Intermediate A via Suzuki coupling. Reduces costs and improves yields for HCV drug manufacturing.
Patent CN115872951A reveals a novel base-catalyzed route for high-purity tianeptine intermediates, offering significant cost reduction and supply chain reliability.
Novel asymmetric hydrogenation route for Apremilast intermediate offering significant cost reduction and supply reliability for pharmaceutical manufacturing partners seeking high-purity intermediates globally.
Novel route avoids benzyl protection, reducing steps and cost for Delgocitinib manufacturing. Ideal for reliable pharmaceutical intermediate suppliers seeking efficiency.
Patent CN104311625B details a cost-effective route for fluocinolone acetate intermediate with high yield and purity for pharmaceutical supply chains.
Patent CN111116531A reveals a novel one-step hydrogenation method for Ramelteon intermediates, offering superior purity and safer processing for pharmaceutical manufacturing.